Update on heparin: what do we need to know?

被引：48

作者：

Weitz, Daniel S. ^{[1
,2
,3
]}

Weitz, Jeffrey I. ^{[1
,2
,3
]}

机构：

[1] Henderson Res Ctr, Hamilton, ON L8V 1V3, Canada

[2] McMaster Univ, Dept Med, Hamilton, ON, Canada

[3] McMaster Univ, Dept Biochem, Hamilton, ON, Canada

来源：

JOURNAL OF THROMBOSIS AND THROMBOLYSIS | 2010年 / 29卷 / 02期

关键词：

Heparin; Low-molecular-weight heparin; Fondaparinux; Parenteral anticoagulants; MOLECULAR-WEIGHT HEPARIN; ACUTE CORONARY SYNDROMES; ACUTE VENOUS THROMBOEMBOLISM; PARTIAL THROMBOPLASTIN TIME; FACTOR-IXA ACTIVITY; UNFRACTIONATED HEPARIN; INDUCED THROMBOCYTOPENIA; RANDOMIZED-TRIAL; PLASMA-PROTEINS; IN-VITRO;

D O I：

10.1007/s11239-009-0411-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Over the last 15 years, there has been a shift from unfractionated heparin to low-molecular-weight heparin or fondaparinux for many indications. Nonetheless, heparin continues to be used and it remains the drug of choice for selected indications and patients. This paper reviews when and how to use heparin and when low-molecular-weight heparin or fondaparinux may be a better choice. The paper also describes some of the new parenteral anticoagulants under development and provides perspective on how the introduction of rapid-acting oral thrombin or factor Xa inhibitors is likely to reduce or eliminate the need for bridging with parenteral anticoagulants.

引用

页码：199 / 207

页数：9

共 51 条

[1] Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin [J].

Bates, SM ;

Weitz, JI ;

Johnston, M ;

Hirsh, J ;

Ginsberg, JS .

ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (03) :385-391

[2] Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites [J].

Bedsted, T ;

Swanson, R ;

Chuang, YJ ;

Bock, PE ;

Björk, I ;

Olson, ST .

BIOCHEMISTRY, 2003, 42 (27) :8143-8152

[3] The effects of standard and low molecular weight heparin on bone nodule formation in vitro [J].

Bhandari, M ;

Hirsh, J ;

Weitz, JI ;

Young, E ;

Venner, TJ ;

Shaughnessy, SG .

THROMBOSIS AND HAEMOSTASIS, 1998, 80 (03) :413-417

[4]

BLACKMER AB, 2009, ANN PHARMACOTHER

[5] Outbreak of Adverse Reactions Associated with Contaminated Heparin [J].

Blossom, David B. ;

Kallen, Alexander J. ;

Patel, Priti R. ;

Elward, Alexis ;

Robinson, Luke ;

Gao, Ganpan ;

Langer, Robert ;

Perkins, Kiran M. ;

Jaeger, Jennifer L. ;

Kurkjian, Katie M. ;

Jones, Marilyn ;

Schillie, Sarah F. ;

Shehab, Nadine ;

Ketterer, Daniel ;

Venkataraman, Ganesh ;

Kishimoto, Takashi Kei ;

Shriver, Zachary ;

McMahon, Ann W. ;

Austen, K. Frank ;

Kozlowski, Steven ;

Srinivasan, Arjun ;

Turabelidze, George ;

Gould, Carolyn V. ;

Arduino, Matthew J. ;

Sasisekharan, Ram .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (25) :2674-2684

[6]

Bousser MG, 2008, LANCET, V371, P315, DOI 10.1016/S0140-6736(08)60168-3

[7]

Buller HR, 2007, NEW ENGL J MED, V357, P1105

[8]

Buller HR, 2007, NEW ENGL J MED, V357, P1094

[9] Fondaparinux or Enoxaparin for the initial treatment of symptomatic deep venous thrombosis -: A randomized trial [J].

Büller, HR ;

Davidson, BL ;

Decousus, H ;

Gallus, A ;

Gent, M ;

Piovella, F ;

Prins, MH ;

Raskob, G ;

Segers, AEM ;

Cariou, R ;

Leeuwenkamp, O ;

Lensing, AWA .

ANNALS OF INTERNAL MEDICINE, 2004, 140 (11) :867-873

[10]

Büller HR, 2003, NEW ENGL J MED, V349, P1695

← 1 2 3 4 5 6 →